KATHERINE DEVARNEY, PH.D.

Corporate Board Profile

Tech Score: 0/100

TITAN PHARMACEUTICALS INC

Filing Date	Source Excerpt
2019-11-20	Katherine DeVarney, Ph.D. (58) has served as an executive officer since February 2019 and has been our executive vice president and chief scientific officer overseeing clinical and medical affairs since November 2018. She joined our company in February 2007 and during her tenure has served in various medical research and development capacities with responsibility for oversight of Titan’s product research and development, regulatory affairs and medical affairs. Dr. DeVarney has over 20 years of experience as a neuroscientist in the pharmaceutical industry, including positions of increasing responsibility with SmithKline Beecham, GlaxoSmithKline, Merck, and Corcept Therapeutics.

Filing Date

Source Excerpt

2019-11-20

Katherine DeVarney, Ph.D. (58) has served as an executive officer since February 2019 and has been our executive vice president and chief scientific officer overseeing clinical and medical affairs since November 2018. She joined our company in February 2007 and during her tenure has served in various medical research and development capacities with responsibility for oversight of Titan’s product research and development, regulatory affairs and medical affairs. Dr. DeVarney has over 20 years of experience as a neuroscientist in the pharmaceutical industry, including positions of increasing responsibility with SmithKline Beecham, GlaxoSmithKline, Merck, and Corcept Therapeutics.

Data sourced from SEC filings. Last updated: 2026-02-03